SYRS: Syros Pharmaceuticals Inc. Company Profile & Statistics

About

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Info & Links

CEO

Conley Chee

Headquarters

35 Cambridge Park Drive, 4th Floor
CAMBRIDGE, MA 02140, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Syros Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization²

5.45M

Enterprise Value

-11.74M

Enterprise Value/EBITDA(ttm)

0.11

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.56

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-4159.18%

Return on Equity(ttm)

-3369.56%

Return on Invested Capital(ttm)

-222.79%

Return on Assets(ttm)

-97.04%

Income Statement

Revenue(ttm)

387.00K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

387.00K

EBITDA(ttm)³

-109.75M

Net Income Available to Common(ttm)

-97.81M

Diluted EPS(ttm)

-3.03

Share Statistics

Beta (5Y Monthly)

1.33

52-Week Change

-92.92%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

26.83M

Dividend Yield

0.00%

Float⁴

23.54M

% Held by Insiders

12.26%

% Held by Institutions

91.47%

Balance Sheet

Total Cash(mrq)

58.27M

Total Cash Per Share(mrq)

2.17

Total Debt(mrq)

41.08M

Total Debt/Equity(mrq)

-369.33%

Current Ratio(mrq)

2.25%

Quick Ratio(mrq)

2.25%

Book Value Per Share(mrq)

-0.41

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.07

Free Cash Flow(ytd)

-81.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SYRS

Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc. Profile